Ligand responsiveness in human prostate cancer: Structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors

Cancer Research

Volumn 60, Issue 9, 2000, Pages 2317-2322

  McDonald, Shawn ^a   Brive, Lars ^a   Agus, David B ^b,c   Scher, Howard I ^b   Ely, Kathryn R ^a  

^a BURNHAM INSTITUTE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING SITE; CANCER CELL; HORMONAL THERAPY; HUMAN; HUMAN CELL; MOLECULAR MODEL; MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; BINDING SITES; HUMANS; LIGANDS; MALE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, PROGESTERONE; SEQUENCE HOMOLOGY, AMINO ACID; TUMOR CELLS, CULTURED;

EID: 0034194341     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Catalona, W. J. Management of cancer of the prostate. N. Engl. J. Med., 331: 996-1004, 1994.
2. Scher, H. I., Liebertz, C., Kelly, W. K., Mazumdar, M., Brett, C., Schwartz, L., Kolvenbag, G., Shapiro, L., and Schwartz, M. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J. Clin. Oncol., 15: 2928-2938, 1997.
3. Hobisch, A., Culig, Z., Radmayr, C., Bartsch, G., Klocker, H., and Hittmair, A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res., 55: 3068-3072, 1995.
4. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinanen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., and Kallioniemi, O. P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet., 9: 401-406, 1995.
5. Scher, H. I., Bentel, J. M., Buchananan, G., Sabattini, P., Weger, M. A., Kelly, W. K., and Tilley, W. Androgen receptor expression in androgen-independent prostate cancer: relation to flutamide withdrawal. Proc. Am. Assoc. Cancer. Res., 37: 245, 1996.
6. Koivisto, P., Kononen, J., Palmberg, C., Tammela, T., Hyytinen, E., Isola, J., Trapman, J., Cleutjens, K., Noordzij, A., Visakorpi, T., and Kallioniemi, O. P. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res., 57: 314-319, 1997.
7. Gottlieb, B., Trifiro, M., Lumbruso, R., and Pinsky, L. The androgen receptor gene mutations database. Nucleic Acids Res. 25: 158-162, 1997.
8. Taplin, M. E., Bubley, G. J., Ko, Y. J., Small, E. J., Upton, M., Rajeshkumar, B., and Balk, S. P. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res., 59: 2511-2515, 1999.
9. Harris, S. E., Rong, Z., Harris, M. A., and Lubahn, D. D. Androgen receptor in human prostate carcinoma LNCap/ADEP cells contains a mutation which alters the specificity of the steroid-dependent transcriptional activation region. Endocrinology, 126 (Suppl.): 93, 1990.
10. Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C., Trapman, J., Brinkmann, A. O., and Mulder, E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens, Biochem. Biophys. Res. Commun., 173: 534-540, 1990.
11. Wainstein, M. A., He, F., Robinson, D., Kung, H. J., Schwartz, S., Giaconia, J. M., Edgehouse, N. L., Pretlow, T. P., Bodner, D. R., and Kursh, E. D. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res., 54: 6049-6052, 1994.
12. Nagabhushan, M., Miller, C. M., Pretlow, T. P., Giaconia, J. M., Edgehouse, N. L., Schwartz, S., Kung, H. J., de Vere White, R. W., Gumerlock, P. H., Resnick, M. I., Amini, S. B., and Pretlow, T. G. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res., 56: 3042-3046, 1996.
13. Suzuki, H., Sato, N., Watabe, Y., Masai, M., Seino, S., and Shimazaki, J. Androgen receptor gene mutations in human prostate cancer. J. Steroid Biochem. Mol. Biol., 46: 759-765, 1993.
14. Agus, D. B., Scher, H. I., Fox, W., Drobnjak, M., Koff, A., Golde, D. W., Cordon-Cardo, C., and Koff, A. Alterations of prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J. Natl. Cancer Inst., 91: 1869-1876, 1999.
15. Lubahn, D. B., Brown, T. R., Simental, J. A., Higgs, H. N., Migeon, C. J., Wilson, E. M., and French, F. S. Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity. Proc. Natl. Acad. Sci. USA, 86: 9534-9538, 1989.
16. Altschul, S. F., Madden, T. L., Schaffer, A. A., Zhang, J., Zhang, Z., Miller, W., and Lipman, D. J. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res., 25: 3389-3402, 1997.
17. Karplus, K., Barrett, C., and Hughey, R. Hidden Markov models for detecting remote protein homologies. Bioinformatics, 14: 846-856, 1998.
18. Thompson, J. D., Higgins, D. G., and Gibson, T. J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res., 22: 4673-4680, 1994.
19. Luisi, B. F., Xu, W. X., Otwinowski, Z., Freedman, L. P., Yamamoto, K. R., and Sigler, P. B. Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature (Lond.), 352: 497-505, 1991.
20. Williams, S. P., and Sigler, P. B. Atomic structure of progesterone complexed with its receptor. Nature (Lond.), 393: 392-396, 1998.
21. Barton, G. J. ALSCRIPT: a tool to format multiple sequence alignments. Protein Eng., 6: 37-40, 1993.
22. Sali, A., and Blundell, T. L. Comparative protein modeling by satisfaction of spatial restraints. J. Mol. Biol., 234: 779-815, 1993.
23. Brooks, B. R., Bruccoleri, R. E., Olafson, B. D., States, J. D., Swaminathan, S., and Karplus, M. CHARMM: a generalized molecular mechanics program. J. Comp. Chem., 4: 187-217., 1983.
24. Dunbrack, R. L., Jr., and Karplus, M. Backbone-dependent rotamer library for proteins. Application to side-chain prediction. J. Mol. Biol., 230: 543-574, 1993.
25. Laskowski, R. A., MacArthur, M. W., Moss, D. S., and Thornton, J. M. PRO-CHECK - a program to check the stereochemical quality of protein structures. J. Appl. Cryst., 26: 283-291., 1993.
26. Christopher, J. A. SPOCK. The Structural Properties Observation and Calculation Kit (Program Manual), The Center for Macromolecular Design, Texas A&M University, College Station, TX, 1998.
27. Merritt, E. A., and Bacon, D. J. Raster3d: Photo-realistic molecular graphics. Methods Enzymol., 277: 505-524, 1997.
28. Lobaccaro, J. M., Poujol, N., Chiche, L., Lumbroso, S., Brown, T. R., and Sultan, C. Molecular modeling and in vitro investigations of the human androgen receptor DNA-binding domain: application for the study of two mutations. Mol. Cell. Endocrinol., 116: 137-147, 1996.
29. Ris-Stalpers, C., Verleun-Mooijman, M. C., Trapman, J., and Brinkmann, A. O. Threonine on amino acid position 868 in the human androgen receptor is essential for androgen binding specificity and functional activity. Biochem. Biophys. Research Commun., 196: 173-180, 1993.
30. Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., and Greene, G. L. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell, 95: 927-937, 1998.
31. Brzozowski, A. M., Pike, A. C., Dauter, Z., Hubbard, R. E., Bonn, T., Engstrom, O., Ohman, L., Greene, G. L., Gustafsson, J. A., and Carlquist, M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (Lond.), 389: 753-758, 1997.
32. Fenton, M. A., Shuster, T. D., Fertig, A. M., Taplin, M. E., Kolvenbag, G., Bubley, G. J., and Balk, S. P. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin. Cancer Res., 3: 1383-1388, 1997.
33. Tan, J., Sharief, Y., Hamil, K. G., Gregory, C. W., Zang, D. Y., Sar, M., Gumerlock, P. H., deVere White, R. W., Pretlow, T. G., Harris, S. E., Wilson, E. M., Mohler, J. L., and French, F. S. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol. Endocrinol., 11: 450-459, 1997.
34. Xu, J., Nawaz, Z., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. The extreme C terminus of progesterone receptor contains a transcriptional repressor domain that functions through a putative corepressor. Proc. Natl. Acad. Sci. USA, 93: 12195-12199, 1996.
35. Nolte, R. T., Wisely, G. B., Westin, S., Cobb, J. E., Lambert, M. H., Kurokawa, R., Rosenfeld, M. G., Willson, T. M., Glass, C. K., and Milburn, M. V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature (Lond.), 395: 137-143, 1998.
36. Moras, D., and Gronemeyer, H. The nuclear receptor ligand-binding domain: structure and function. Curr. Opin. Cell Biol., 10: 384-391, 1998.